We have identified a soluble form of the human urokinase plasminogen activator (uPA) receptor (uPAR) in the ascitic fluids from patients with ovarian cancer. After purification of uPAR from the ascitic fluids by ligand-affinity chromatography (prouPA Sepharose), the uPAR was initially identified by crosslinking to a radiolabeled amino-terminal fragment of human uPA. The uPAR purified from the ascitic fluid has no bound ligand (uPA), as similar amounts can be purified by ligand-affinity chromatography as by immuno-affinity chromatography. uPAR from ascitic fluids partitions in the water phase after a temperature-dependent phase separation of a detergent extract. It therefore lacks at least the lipid moiety of the glycophospholipid anchor present in cellular-bound uPARs. It is highly glycosylated and the deglycosylated form has the same electrophoretic mobility as previously characterized cellular uPAR from other sources. The immunoreactivity of the purified uPAR from the ascitic fluid is indistinguishable from that of characterized uPAR, demonstrated by Western blotting with three different anti-uPAR monoclonal antibodies. The uPAR was found in 11 of 11 ascitic fluids from patients with ovarian cancer and in elevated amounts in the plasma from 2 of 3 patients. The concentration of soluble uPAR in the ascitic fluid was estimated to range between 1 and 10 ng/ml. Human soluble uPAR, derived from the tumor cells, was also found in the ascitic fluid and serum from nude mice xenografted intraperitoneally with three different human ovarian carcinomas. (J. Clin. Invest. 1993.92:2160-2167.) Key words: ovarian cancer. urokinase plasminogen activator receptor * ascitic fluid * plasma.
Introduction
Physiological and pathological invasive processes correlate with or depend on the activity of proteolytic enzymes, particularly plasminogen activators ( 1, 2) . For some tumor cells the invasive and metastatic behavior in vivo and in vitro can be modulated by artificially modifying (i.e., increasing or decreas-Receivedfor publication 22 June 1992 and in revisedform 22 June 1993.
ing) the activity of the urokinase-type plasminogen activator (uPA)' ofthe cells (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . uPA is localized at the leading edge ofexperimental and human malignant tumors, ofthe implanting embryo, and of migrating macrophages (13) (14) (15) (16) (17) .
Localization of the uPA activity to the cell surface of normal and neoplastic cells depends on the presence of a specific cell surface receptor for uPA (uPAR) (18) , which can be located in some cultured cells at the cell-to-substratum and cellto-cell contacts (19, 20) . uPAR is a 50-60-kD, single chain, highly glycosylated, and glycosyl phosphatidyl-inositol (GPI)-anchored cell surface protein (21) (22) (23) . Binding to cellular uPAR increases the rate of activation of pro-uPA at least 20-fold both in vivo and in vitro (24, 25 ) . Surface-associated uPA activity is controlled by uPAR through the selective internalization and degradation ofuPA/inhibitor complexes, whereas active uPA and pro-uPA are not internalized by the receptor ( 16, (26) (27) (28) . Thus, uPAR plays an important role in regulating the surface activity of uPA and the cellular localization of active extracellular proteolysis. uPAR has also been suggested to transduce regulatory signals modifying the growth and the adhesive state of cells (29, 30) . For all these reasons, uPAR is a central molecule in uPA-dependent biological functions as shown by direct complementation studies between uPA and uPAR (25, 31) . Such complementation may occur by both paracrine and autocrine mechanisms in vitro and in human tumors (17, 32, 33) .
Compared with benign tumors, cancer tissues have been known to produce high levels ofplasminogen activators, particularly uPA (reviewed in references 2 and 34) . Recently, the measurement of the uPA content in primary breast cancer extracts has been demonstrated to be an independent, statistically significant, prognostic factor predictive for early relapse and overall survival (35) (36) (37) (38) (39) (40) . In many cultured cancer cells the level of uPAR is high and it can be further increased by tumor promoters and growth factors (41) (42) (43) Circulating, soluble forms of cell surface receptors with ligand-binding properties have been described (46) (47) (48) (49) (50) (51) (52) . The presence of a naturally occurring, circulating, soluble form of uPAR has been demonstrated in plasma from patients with paroxysmal nocturnal hemoglobinuria (53) . These patients are deficient in synthesis or processing ofGPI anchors, which is a characteristic of cell surface-bound uPAR. However, in the mouse an alternatively spliced mRNA, coding for a putative soluble form of uPAR, has been described (54) . In this paper we demonstrate that a soluble, hydrophilic, and ligand-free form of uPAR is present in the ascitic fluid and plasma from patients with highly invasive ovarian carcinomas. We also demonstrate the presence of human uPAR in the ascitic fluid and serum of nude mice xenografted intraperitoneally with three different human ovarian carcinomas.
Methods
Materials. Highly purified recombinant pro-uPA expressed in Escherichia coli was kindly donated by Dr. Paolo Sarmientos (Farmitalia Carlo Erba, Milan, Italy). The amino-terminal fragment of uPA (ATF) was a kind gift of Dr. Jack Henkin (Abbott Laboratories, Chicago, IL). Hybridomas producing monoclonal antibodies to human uPAR (R2, R3, and R4) have been described previously (55 (21 ) and PMA-stimulated human U937 cells were grown and lysates were made as previously described (23) . The mouse LB6-Cl.4. 19 cells producing a recombinant, soluble, secreted form of human uPAR (s-uPAR) were grown, and conditioned medium was collected as previously described (56) .
Ascitic fluid and plasma preparation. The ascitic fluid or plasma from patients with ovarian cancer was cleared by centrifugation (3,000 g for 10 min) and stored at -20'C. The patients C.B. and E.H. belonged to clinical stage 1, patients H.S., M.F., G.K., E.W., M.W., and U.E. to stage 3, and patients K.S., M.M., J.F., and K.W. to stage 4. Some ascites preparations contained anticoagulants. Bacterial phosphatidyl-inositol-specific phospholipase C (PIPLC) treatment of the ascitic fluid was with 0.05 U/ml at 37°C for 12 h.
Purification ofuPAR with pro-uPA Sepharose or anti-uPAR monoclonal antibody Sepharose. Pro-uPA Sepharose was prepared by coupling highly purified recombinant pro-uPA to CNBr-activated Sepharose 4B (1 mg pro-uPA/ml CNBr-Sepharose) according to the procedure recommended by Pharmacia Fine Chemicals. Thawed ascitic fluid or plasma samples were cleared at 3,000 g for 10 min, 3-[(3-cholamidopropyl) dimethyl-ammonio]-1-propanesulfonic acid (CHAPS) was added to a final concentration of0.1%, and aprotinin to 0.3 trypsin inhibitor units (TIU)/ml. The samples were incubated overnight at 4°C with pro-uPA Sepharose (50 Ml resin/ml of ascitic fluid or plasma). The resin was washed twice in 1 ml PBS containing 0.1% CHAPS and once in 1 ml 10 mM Na-phosphate buffer, pH 7.4, containing I M NaCl. The uPAR was eluted at room temperature with 200 il 0.1 M acetic acid, 0.5 M NaCl, 0.1% CHAPS, pH 2.6, and either neutralized with Trizma base or precipitated with 3 vol of acetone overnight at -20°C with 20 1 g cytochrome C as carrier.
uPAR was alternatively purified on anti-uPAR monoclonal antibody R2 (55) coupled to protein G-Sepharose (0.5 mg/ml protein G-Sepharose) as described above, except that the samples were preincubated with protein G-Sepharose (2 h at 4VC) and the supernatant was used for further purification (E. R0nne, unpublished results).
Detergent phase separation. Ascites or plasma samples were brought to 0.1 M Tris-HCI, pH 8.1, 10 mM EDTA, and 1% (wt/vol) Triton X-1 14 on ice. Temperature-dependent phase separation was carried out as described previously (23) and uPAR was purified from the two phases with pro-uPA Sepharose as described above.
Crosslinking of uPAR to '25I-A TF. ATF was iodinated with Iodogen to a specific activity of 10-15 mCi '25I/mg. ATF-containing amino acids 1-135 or 1-143 were used in different experiments. Eluates from pro-uPA Sepharose corresponding to 0.5 ml ascitic fluid or plasma (unless otherwise stated) were added to 50,000 cpm of '25I-ATF at 4VC for 1-3 h in the presence or absence of 100 nM unlabeled uPA or pro-uPA as competitor to assess binding specificity. The samples were subsequently crosslinked with DSS and analyzed by 12.5% acrylamide SDS-PAGE and autoradiography as previously described (23) .
Deglycosylation of uPAR crosslinked to '25I-A TF. Removal of Nbound carbohydrates was performed on crosslinked '251I-ATF/uPAR complexes. Treatment with PNGase F was performed as described (23) , except the incubation was for 5 h. Samples treated with Endo H were adjusted to include 0.2% SDS and 50 mM sodium citrate, pH 5.5. Endo H (0.1 U/ml) was added and the samples were incubated at 37°C for 4 h.
Immunoblotting. uPAR from 8 ml ascitic fluid was purified on pro-uPA Sepharose, acetone precipitated, and dissolved in SDS-PAGE sample buffer without ,B-mercaptoethanol (57). 350 Ml LB6-Cl.4.19 medium containing s-uPAR was acetone precipitated and dissolved in the same sample buffer. The samples were separated by 12.5% acrylamide SDS-PAGE and blotted onto nitrocellulose membranes, the blots blocked in PBS containing 2% low-fat dry milk, and incubated with monoclonal anti-uPAR antibodies (RI, R2, R3, and R4 [23 ] , each at -0.3 Mg/ml, either as a mixture or separately). The filters were washed and developed using the Vectastain peroxidase kit.
Intraperitoneal xenografting ofhuman ovarian carcinoma cell lines into nude mice. Female NCr-n u/nu mice were obtained from the animal production colony of the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD) and used when 8-10 wk old. Throughout this study nude mice were housed in air-filtered laminar-flow cabinets and manipulated according to aseptical procedures. HOC8 cells were derived from pleural effusion, and HOC10 and HOC22 were from ascites of patients with ovarian carcinoma. The HOC lines were established and maintained as ascites in nude mice as described previously (58, 59) . 107 cells of the HOC cell lines were injected as a suspension intraperitoneally in nude mice. Blood and ascites were collected 30 d later (two mice per cell line). Blood was obtained by intracardiac puncture from anesthesized mice and the serum collected after centrifugation at 3,000 rpm for 10 min. Mice were killed and ascites harvested with 3 ml of 0.9% NaCl and centrifuged at 1,200 rpm for 10 min. Serum and peritoneal lavage were obtained from non-tumor-bearing animals and processed in the same way. Serum and ascitic fluid were stored at -80°C until analysis. uPAR from serum and ascitic fluid (100 Ml) was purified on pro-uPA Sepharose and crosslinked to '251-ATF as described above. (Fig. 1) . The uPA binding protein from the ascitic fluids has the same apparent molecular mass as uPAR and can be deglycosylated in a similar manner. We next compared the electrophoretic mobility of the uPA binding protein purified on pro-uPA Sepharose from ascitic fluid with that of uPAR present in extracts from PMA-stimulated monocyte-like U937 cells, the osteosarcoma cell line Saos-2, or with s-uPAR. As shown in (Fig. 2) . PNGase F treatment gave the same result for uPA binding protein purified from ascitic fluids from three other patients (G.K., E.W., and K.G.) (data not shown). The sensitivity to PNGase F shows that the glycosylation is of the complex type. As is the case for cell surface-associated uPAR, the uPA binding protein from the ascitic fluid is insensitive to Endo H (62) (Fig. 2) The uPA bindingprotein has the same immunoreactivity as uPAR. We next tested whether the soluble uPA binding protein was immunologically related to uPAR. We first used a mixture of four different monoclonal antibodies (RI, R2, R3, and R4) raised against the uPAR purified from the PMA-stimulated U937 cells. These antibodies were previously shown to recogCnize either the amino-or the carboxy-terminal moieties of uPAR (55) . The uPA binding protein was purified from ascitic fluid from three patients and subjected to nonreducing SDS-PAGE and immunoblotted with the mixture of Rl, R2, R3, and R4 monoclonal antibodies (Fig. 3) . A positive reaction with the antibodies was observed for all three patients, showing a band migrating at 45-50 kD. As a positive control, s-uPAR from LB6-Cl. 4 Figure 3 . The ascitic fluid from ovarian cancer patients contains a protein that is recognized by monoclonal antibodies raised against uPAR from human U937 cells. The pro-uPA Sepharose eluate of 8 ml ascitic fluid from three patients (as indicated) was run on nonreducing SDS-PAGE, transferred to nitrocellulose, and immunoblotted using a mixture of the anti-uPAR monoclonal antibodies (RI, R2, R3, and R4). Positive control is the acetone-precipitated medium from s-uPAR-producing LB6-Cl.4.19 cells, and negative control is the eluate from a mock pro-uPA Sepharose purification. separation (23) . Removal of the lipid moiety of the uPAR from U937 or LB6-Cl.19 cells by PIPLC, however, causes uPAR to partition with the water phase (22). The same watersoluble behavior is observed with recombinant uPAR mutants lacking the GPI anchor or when the wild-type protein is expressed in a GPI-deficient cell line (56, 64) . To test whether the uPAR from ascitic fluid was in a membrane-bound form (e.g., in shedded vesicles), we used the same approach. LB6-Cl. 19 cells (Cl. 19) expressing the wild-type GPI-anchored uPAR were used as control. As shown in Fig. 4 by crosslinking with 125I-ATF, only the detergent phase (lanes D) of LB6-Cl. 19 Triton X-114 lysate contains uPAR. Freezing and thawing the cells before detergent lysis did not change the partitioning (not shown). We therefore subjected the ascitic fluid to Triton X-114 treatment and phase separation. The water and detergent phases were incubated with pro-uPA Sepharose and the eluates crosslinked to '251-ATF. uPAR from the ascitic fluid was detected only in the water phase (lanes W). Pretreatment ofthe ascitic fluid with PIPLC made no difference in partitioning. Fig. 4 shows uPAR purified from the ascitic fluid ofpatient M.W., but identical results were obtained with ascitic fluid from three other patients (G.K., E.W., and K.G.). 19) , which express the GPI-anchored uPAR, was phase separated and each phase was crosslinked to '251-ATF as above.
Results
As all samples in this experiment were cleared by centrifugation at 3,000 g before any treatment, the uPAR cannot be cell bound. Centrifugation of the ascitic fluids at 150.000 g before purification gave no loss of uPAR, indicating that the uPAR is not associated with membrane debris. We also verified that the presence of anticoagulants, or the freeze-thawing procedure to which the ascitic fluids had been subjected, did not affect the phase partitioning of uPAR expressed in LB6-Cl. 19 cells (data not shown). We conclude, therefore, that the ascitic fluid of ovarian cancer patients contains a water-soluble form ofuPAR missing the lipid moiety of the GPI anchor.
uPAR is present in all analyzed asciticfluidsfrom patients with ovarian cancer. We have extended this study and analyzed ascitic fluid from a total of 11 patients with ovarian cancer for the presence of the soluble uPAR. Fig. 5 shows the '251-ATF crosslinked uPAR purified from ascitic fluid using immuno-affinity chromatography (R2-protein G-Sepharose). Identical results were obtained using ligand-affinity chromatography (pro-uPA Sepharose). Ligand-bound uPAR retains its ligand during the purification with pro-uPA Sepharose and cannot be detected by crosslinking to 1251-ATF (data not shown). In all cases, we detected uPAR with the same electrophoretic migration (all from 0.5 ml of ascitic fluid). Elevated amounts of soluble uPAR (purified from 0.5 ml plasma on R2-protein G-Sepharose) was also detected in the plasma of two of three ovarian cancer patients as compared with plasma from a healthy person. In the case shown, the level of uPAR from plasma of a healthy person is higher than previously found using pro-uPA Sepharose for purification (data not shown, and reference 53) . uPAR from the plasma also partitioned into the water phase in detergent phase separation (not shown).
We have quantitated the amount of soluble uPAR in the ascitic fluid from three patients (G.K., E.W., and M.W.) by an ELISA for uPAR (E. R0nne et al., unpublished results) using pro-uPA Sepharose purified uPAR from the ascitic fluid, compared with a known amount of s-uPAR purified in the same manner. The level of uPAR in these samples range from 2.5 to 3.5 ng/ml (data not shown). Mixing a known amount ofpurified s-uPAR to the ascitic fluid before the purification gave an ASCITIC FLUID .FI Oms m L~Wj~e -i =i6 ui :g additive value. By comparing the relative amounts of crosslinked uPAR from the different patients and a known amount of s-uPAR, we estimate the concentration of uPAR in the ascitic fluids to range from 1 to 10 ng/ml, and in the plasma (patients J.F. and K.W.) to be in the order of0.05 ng/ml, while that of the control plasma was 0.01 ng/ml. Ascitic fluid and serum from nude mice bearing human ovarian tumor xenografts contains soluble, human uPAR. In the case ofthe human patients, it was not possible to determine the source of the soluble uPAR in the ascitic fluids. It could derive from the tumors themselves, but could also derive from macrophages or other cells in the peritoneum. To determine the possibility that the soluble uPAR is derived from the tumor cells, we tested three human ovarian carcinoma xenografts transplanted intraperitoneally into nude mice. The carcinoma cell lines grow in the peritoneal cavity of nude mice and all produce ascites. Histopathological characteristics of the patients' primary tumor were maintained in nude mice (59) . At 30 d after transplant, HOC8 and HOC22 caused massive invasion of the peritoneal organs, while only microscopic tumor deposits were observed in mice bearing HOC10.
Serum and ascitic fluid was collected from tumor-bearing mice. 100 ,l of each sample was purified on pro-uPA Sepharose and analyzed by crosslinking to '251-ATF in exactly the same manner as from human patients (Fig. 6) . Human 1251. ATF cannot be crosslinked to the mouse uPAR (65) . Therefore, the crosslinked products can only be attributed to human uPAR present in the mouse samples. As expected, there is no crosslinkable uPAR in the serum or ascitic fluid of control tumor-free mice. However, there is detectable uPAR in the ascitic fluid of HOC I0-xenografted mice and even higher amounts with HOC22-and HOC8-xenografted mice. In the serum, uPAR is undetectable with mice xenografted with HOC10, but clearly detectable with HOC22 and HOC8. The size of the '25I-ATF/uPAR complex is 70-80 kD for all the complexes, which is the same size as for uPAR from other cells, and the formation is competed by 100 nM unlabeled uPA. Duplicate mice in each experiment gave comparable results The ascitic fluid uPAR is recognized by the monoclonal antibody R3 and binds the ligand. Since both recognition sites are located at the amino terminus (55, 66) , one would expect any structural differences, if present, to be most likely localized at the carboxy terminus, which contains the GPI attachment signal (22). However, the uPAR is also recognized by the monoclonal antibodies R2 and R4, which recognize a region different from the amino terminus (55) . In fact, cDNA coding for a possibly soluble form ofuPAR and arising as a result ofalternative splicing of uPAR mRNA has been isolated from a mouse cDNA library, although the protein itself has not yet been detected (54) . The cDNA sequence shows that this form should contain the amino-terminal, ligand-binding part of the membrane-attached uPAR, but is missing the carboxy-terminal portion, including the GPI attachment and signal regions, which are replaced by a nonhydrophobic sequence. The putative product ofthis mRNA has not been observed yet, but is expected to have ligand-binding properties and to be secreted in a water-soluble form. The possibility exists, therefore, that the s-uPAR from the ovarian cancer ascitic fluids represents the product of a similar alternative splicing. It appears more likely, however, that ascitic fluid uPAR is the result ofa protease-or phospholipase-mediated shedding of cellular receptor. This question can best be solved by the determination ofthe amino acid composition of uPAR from ascitic fluid. The presence ofhuman uPAR in the ascitic fluid and plasma from nude mice xenografted with human ovarian carcinomas shows that, at least in this experimental system, the human s-uPAR derives from the tumor cells, as these are the only human cells in the mouse. Although the amount ofuPAR present on the carcinomas used in this experiment have not yet been determined before xenografting, uPAR has previously been shown to be increased in malignant vs. benign ovarian tumors (45) and to be present in ovarian carcinoma cell lines (67, 68) . And, indeed, the occurrence of soluble receptor was higher in the ascitic fluid and serum from mice bearing the more invasive xenografts (HOC22 and HOC8) .
The plasma concentration ofuPA is in the order of -1 nM (69, 70) , close to the dissociation constant for uPA/uPAR interaction ( 18) . Therefore, ligand-bound uPAR may also be present in the ascitic fluid or plasma of ovarian carcinoma patients or in the plasma of healthy volunteers. This could account for the higher amount of uPAR detected in the plasma from a healthy person, when the uPAR was purified on R2 antibody Sepharose compared with pro-uPA Sepharose. The apparent accumulation of uPAR in the plasma of some patients, and in the nude mice injected with human tumors, indicates that the s-uPAR has a rather long half-life. If this is the case, s-uPAR in the plasma could contribute to increase the half-life of circulating pro-uPA. Although an increase in uPA production has been determined for patients with ovarian cancer, the increase was mostly observed in the tumor and cystic liquid, and not in the ascitic fluid (68) . This is in agreement with our finding that the majority of the uPAR in the ascitic fluid is not associated with uPA, as the amounts of uPAR purified by R2 antibody and pro-uPA Sepharose were not significantly different. In conclusion, we have shown that a s-uPAR circulates in biological fluids of ovarian cancer patients and that a simple procedure can be used for its quantitation in plasma, serum, and ascitic fluid. The data presented in this paper suggest that the presence of uPAR may be related to the malignant phenotype and that the uPAR found in the ascitic fluid and plasma may derive from the tumors. The observation that human ovarian tumor cell lines produce high amounts of human s-uPAR in the ascitic fluid and serum of nude mice provides a model system that will help to identify the mechanism causing the accumulation ofs-uPAR. Also, this model system can be used to investigate a possible correlation between the amount of s-uPAR and the progression of the tumor growth and malignancy. To establish whether the presence of s-uPAR in biological fluids can be used as a parameter for the diagnosis or prognosis of the disease, a higher number of patients (including other groups of patients) is needed.
